Comparing the Antiseizure and Neuroprotective Efficacy of LY293558, Diazepam, Caramiphen, and LY293558-Caramiphen Combination against Soman in a Rat Model Relevant to the Pediatric Population

The Journal of Pharmacology and Experimental Therapeutics
James P AplandMaria F M Braga

Abstract

The currently Food and Drug Administration-approved anticonvulsant for the treatment of status epilepticus (SE) induced by nerve agents is the benzodiazepine diazepam; however, diazepam does not appear to offer neuroprotective benefits. This is of particular concern with respect to the protection of children because, in the developing brain, synaptic transmission mediated via GABAA receptors, the target of diazepam, is weak. In the present study, we exposed 21-day-old male rats to 1.2 × LD50 soman and compared the antiseizure, antilethality, and neuroprotective efficacy of diazepam (10 mg/kg), LY293558 (an AMPA/GluK1 receptor antagonist; 15 mg/kg), caramiphen (CRM, an antimuscarinic with NMDA receptor-antagonistic properties; 50 mg/kg), and LY293558 (15 mg/kg) + CRM (50 mg/kg), administered 1 hour after exposure. Diazepam, LY293558, and LY293558 + CRM, but not CRM alone, terminated SE; LY293558 + CRM treatment acted significantly faster and produced a survival rate greater than 85%. Thirty days after soman exposure, neurodegeneration in limbic regions was most severe in the CRM-treated group, minimal to severe-depending on the region-in the diazepam group, absent to moderate in the LY293558-treated group, and totally absent in ...Continue Reading

References

Sep 1, 1979·Archives of Neurology·R E RamsayB J Wilder
Mar 1, 1991·Brain Research Bulletin·M J PontecorvoJ W Ferkany
Mar 1, 1972·Electroencephalography and Clinical Neurophysiology·R J Racine
Dec 1, 1980·Journal of Neuroscience Methods·G PaxinosP C Emson
Feb 16, 1993·European Journal of Pharmacology·R L HudkinsD L DeHaven-Hudkins
Nov 14, 1997·Neuroscience and Biobehavioral Reviews·J H McDonough, T M Shih
Dec 31, 1997·Annals of Internal Medicine·Y SekijimaN Yanagisawa
Oct 28, 1998·Journal of Physiology, Paris·G LallementG Blanchet
May 29, 1999·Journal of Microscopy·H J Gundersen Nielsen J
Jul 13, 1999·Journal of Neurophysiology·D G Rainnie
Sep 24, 1999·Pharmacology, Biochemistry, and Behavior·T M Shih, J H McDonough
Sep 15, 2001·The European Journal of Neuroscience·A VazdarjanovaJ L McGaugh
Nov 13, 2002·Neurology·Gregory L Holmes
Feb 26, 2003·European Journal of Pharmacology·Laetitia Prut, Catherine Belzung
Apr 15, 2003·Toxicology and Applied Pharmacology·Tsung-Ming ShihJohn H McDonough
May 2, 2003·Annals of the New York Academy of Sciences·Anantha ShekharDonald G Rainnie
May 7, 2003·Neuroscience and Biobehavioral Reviews·Susan L Andersen
Jul 2, 2003·Toxicological Sciences : an Official Journal of the Society of Toxicology·Lily RavehBen Avi Weissman
Jul 5, 2003·Physiological Reviews·P SahJ Power
Jul 31, 2003·Epilepsia·Howard P GoodkinGregory L Holmes
Dec 3, 2003·Annals of the New York Academy of Sciences·Christina Kanaka-GantenbeinGeorge P Chrousos
Dec 18, 2003·Annals of the New York Academy of Sciences·Spiros FourlanosLeonard C Harrison
Jun 17, 2004·Drug and Chemical Toxicology·Benedict R CapacioJ H McDonough
Dec 17, 2004·Psychiatry and Clinical Neurosciences·Toshiyuki OhtaniNobumasa Kato
Jun 10, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Howard P GoodkinJaideep Kapur
Aug 12, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jay F MullerAlexander J McDonald
Aug 27, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·David E NaylorClaude G Wasterlain
May 16, 2006·Current Opinion in Neurobiology·Shin Kwak, John H Weiss
Sep 12, 2006·Journal of the Neurological Sciences·N YanagisawaT Nakajima
Mar 16, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yitao LiuYu Tian Wang
Aug 7, 2007·Biochemical and Biophysical Research Communications·Kyungjoon ParkKi Soon Shin
Mar 6, 2008·Toxicology and Applied Pharmacology·Lily RavehRachel Brandeis
Apr 1, 2008·Lancet·Murray B Stein, Dan J Stein
Sep 17, 2008·Neuropharmacology·David E JaneGraham L Collingridge

❮ Previous
Next ❯

Citations

Apr 3, 2020·Annals of the New York Academy of Sciences·Marcio De Araujo FurtadoMaria F M Braga
Dec 20, 2018·Epilepsia Open·Kerry W ThompsonClaude G Wasterlain
Feb 25, 2019·Neurobiology of Disease·Vassiliki Aroniadou-AnderjaskaMaria F Braga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.